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Abstract: BRCA1 is a tumor suppressor which plays a crucial role in the repair of DNA double-strand breaks, and its 
abnormality is responsible for hereditary ovarian cancer syndrome. It has recently been reported that reduced expression 
of BRCA1 is also common in sporadic ovarian carcinoma via its promoter hypermethylation, and that ovarian carcinoma 
patients negative for BRCA1 expression showed favorable prognosis. To address if BRCA1 expression plays a role in the 
chemotherapeutic response, we analyzed the effect of BRCA1 suppression on the sensitivity to cisplatin and paclitaxel in 
ovarian cancer cells. Speciﬁ  c siRNA for BRCA1 gene was transfected into 3 ovarian cancer cell lines with various p53 
status. Reduced expression of BRCA1 by transfection of BRCA1-siRNA resulted in a 5.3-fold increase in sensitivity
 to 
cisplatin in p53-wild A2780 cells, but not in p53-mutated A2780/CDDP and p53-deleted SKOV3 cells. Regarding the 
sensitivity to paclitaxel, BRCA1 suppression caused no signiﬁ  cant changes in all the 3 cell lines. For ionizing radiation 
sensitivity, BRCA1 suppression also showed a signiﬁ  cant higher sensitivity in A2780 cells. Growth curve and cell cycle 
analyses showed no signiﬁ  cant differences between BRCA1-siRNA-transfected A2780 cells and control cells. However, 
cisplatin treatment under suppression of BRCA1 showed a signiﬁ  cantly increased apoptosis along with up-regulation of 
p53 and p21 in A2780 cells. Accordingly, reduced expression of BRCA1 enhances the cisplatin sensitivity and apoptosis 
via up-regulation of p53 and p21, but does not affect the paclitaxel sensitivity. Expression of BRCA1 might be an important 
biomarker for cisplatin resistance in ovarian carcinoma.
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Introduction
Epithelial ovarian carcinoma is the leading cause of death from gynecological cancer (Ozols et al. 
2000). BRCA1 is a tumor suppressor gene responsible for hereditary ovarian cancer syndrome (Miki 
et al. 1994), and has been shown to regulate the maintenance of genome integrity, cell cycle control, 
apoptosis and DNA repair (Wang et al. 2000; Scully et al. 2000). Although somatic mutation of the 
BRCA1 gene has rarely been detected (Futreal et al. 1994; Merajver et al. 1995; Berchuck et al. 1998), 
decreased expression of the BRCA1 mRNA and protein (Thompson et al. 1995; Zheng et al. 2000; 
Russell et al. 2000), allelic loss or loss of heterozygosity (LOH), and methylation of the BRCA1 
promoter region have recently been reported in sporadic ovarian carcinomas (Catteau et al. 1999; 
Esteller et al. 2000; Baldwin et al. 2000; Geisler et al. 2002; Wang et al. 2004). In addition, several 
studies have reported better survival in patients with hereditary BRCA1-associated ovarian carcinoma 
compared with those with sporadic carcinoma (Boyd et al. 2000; Ben David et al. 2002; Rubin 1996). 
Even among sporadic ovarian carcinomas, we showed that patients with advanced ovarian carcinoma 
negative for BRCA1 expression tended to show better survival than those with carcinoma positive 
for BRCA1 (Wang et al. 2004). These ﬁ  ndings suggest that patients with BRCA1-negative carcinoma 
respond well to chemotherapy. To explore the role of BRCA1 gene in the response to chemotherapy, 
we analyzed the effect of BRCA1 suppression by BRCA1-speciﬁ  c siRNA on the sensitivity to anti-
cancer agents such as cisplatin and paclitaxel, as well as to ionizing radiation in ovarian cancer cells 
with different p53 status.
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Materials and Methods
Ovarian cancer cells
The ovarian cancer cell lines SKOV3 and OVCAR3 
were purchased from the ATCC (Rockville, MD). 
The ovarian cancer cell lines A2780 and A2780/
CDDP (a cisplatin-resistant cell line derived 
from A2780) were kind gifts from Dr. Takashi 
Tsuruo (Cancer Chemotherapy Center, Tokyo, 
Japan)(Tsuruo et al. 1986) with the permission of 
Dr. Thomas C. Hamilton (Fox Chase Cancer Insti-
tute, Philadelphia, PA). A2780 and A2780/CDDP 
were maintained in PRMI 1640 (Sigma, St. Louis, 
MO) supplemented with 10% fetal bovine serum 
(FBS) (Biomeda, Foster City, CA). SKOV3 was 
cultured in Dulbecco’s modiﬁ  ed Eagle’s medium 
(DMEM) (Sigma) with 10% FBS. Incubation was 
carried out at 37°C under 5% CO2 in air.
siRNA and transfection
BRCA1 siRNA sequences were identiﬁ  ed
 using 
the Dharmacon website (Dharmacon Research,
 
Lafayette, CO). SI20 (UGC ACU AGC CUC ACA 
CAU AdTdT), a scrambled version
 of SI20 (SCR) 
(CCU ACU AAG CGA CAC CAU UdTdT), 
or the control luciferase siRNA (UAAGGCU-
AUGAAGAGAUACdTdT) were used in this 
study.
 Ovarian cancer cells were transfected with 
siRNA duplexes by using Oligofectamine
 (Invit-
rogen Carisbad CA), following the manufacturer’s 
instructions.
RNA Extraction and RT-PCR 
Total RNA was extracted by the acid guanidinium-
phenol-chloroform method as described previously 
(Horiuchi et al. 2003). One microgram of total 
RNA was treated with 1 U/10 nl DNase I (Life 
Technologies, Gaithersburg, MD).
Reverse transcription and polymerase chain 
reaction (RT) was performed using an RNA 
PCR Kit (Takara Shuzo, Otsu, Japan), the 1 ng 
RNA sample being added to 20 nl of a reaction 
mixture consisting of 10 mM Tris-HCl (pH 8.3), 
50 mM KCl, 5 mM MgCl2, 1 mM dNTP mixture,
1 unit/nl of RNase inhibitor, 0.25 units/nl of avian 
myeloblastosis virus-derived reverse transcrip-
tase, and 0.125 nM of oligo d(T)-adaptor primer. 
Using a thermal cycler (Perkin Elmer, Gene Amp 
PCR System 2400-R, Norwalk, CT), the reaction 
mixture was incubated at 42°C for 30 minutes, 
heated at 99°C for 5 minutes, and then cooled down 
to 5°C for 5 minutes.
One microliter of the RT products, containing 
50 ng reverse transcribed total RNA, was ampliﬁ  -
cated by adding 20 nl of PCR reaction mixture 
containing 10 mM Tris-HCl (pH 8.3), 50 mM 
KCl, 2.5 units/100 nl of TaKaRa Taq DNA poly-
merase, with 0.2 nM of a set of oligonucleotide 
primers. Primers were synthesized to encom-
pass a speciﬁ  c segment of the cDNA sequence 
of the BRCA1, (sense, 5'-TGAGGCATCAGT
CTGAAAGCC-3' and antisense, 5'-CTGAT
GTGCTTTGTTCTGGA-3'), or of G3PDH (glyce- 
raldehyde-3-phosphate dehydrogenase) (sense,
5'-ACGACCACTTTGTCAAGCTC-3' and anti-
sense 5'-TCACA GTTGCCATGTAGACC-3', 
spanning between exons 7 and 8). The corre-
sponding cDNA fragments were denatured at 94°C 
for 30 seconds, annealed at 58°C for 1 minute, and 
extended at 72°C for 1 minute. After 35 cycles of 
ampliﬁ  cation, the PCR products were analyzed on 
a 2% agarose gel, and the bands were visualized 
using ethidium bromide during exposure to an 
ultraviolet transilluminator.
Drug sensitivity assay
WST-1 assay was employed for the assessment of 
drug sensitivity. SKOV3, A2780 and A2780/CDDP 
cells were seeded onto 96-well tissue culture
 plates 
at a density of 10,000 cells/well. After 24 hours, 
cells
 were incubated in medium supplemented with 
the described
 concentration ranges of cisplatin 
(Sigma) and paclitaxel (Bristol Myers Squibb). 
After 72 hours of continuous drug exposure, 
cultured cells were incubated with WST-1 reagent 
(Roche, Indianapolis, IN) at a dilution of 1:10 in 
the original conditioned media for 4 hours. After 
thorough shaking, the formazan produced by the 
metabolically active cells in each sample was 
measured at a wavelength of 450 nm with Multi-
scan JX (Thermo Labsystems, Vantee, Finland). 
Absorbance readings were normalized against 
control wells with medium alone.
Cell cycle analysis
We used FACScan for the cell-cycle analysis. 
Forty-eight hours after siRNA transfection, each 
group of cells was collected and washed with 
PBS(-) three times. The cells were ﬁ  xed in 70% 
ethanol. Then, the cells were resuspended in a 
DNA-stain solution containing propidium iodide 
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(20 mg/ml; Calbiochem, CA, U.S.A) and RNAase 
(1.8 units/ml; Sigma, St. Louis, MO, U.S.A). The 
cells were analyzed with a FACScan (Fluorescence 
Activated Cell Sorter) ﬂ  ow cytometer equipped 
with an argon laser (488 nm; Becton Dickinson 
Immunocytometry System, Mountain View, CA, 
U.S.A). The experiments were repeated three 
times.
Western blot analysis
Cells were lysed in a lysis buffer: 50 mM Tris-
HCl, pH 8.0, 0.25 M NaCl, 0.5% NP-40, 1 mM 
PMSF (Sigma), 1 ng/ml aprotinin (Boehringer 
Mannheim, Germany), 1 ng/ml leupeptin (Boeh-
ringer Mannheim), and 20 ng/ml TPCK (Boeh-
ringer Mannheim). The lysates were centrifuged 
at 13,000 rpm for 20 minutes at 4°C and the super-
natants were stored at –80°C. Extracts equivalent 
to 50 ng of total protein were separated by SDS-
polyacrylamide gel electrophoresis (8% acryl-
amide) and transferred onto nitrocellulose 
membranes (Hybond TM-C super, Amersham, 
U.K.). The membranes were blocked in TBST 
(0.2M NaCl, 10mM Tris, pH 7.4, 0.2% Tween-20) 
containing 5% non-fat dry milk and 0.02% NaN3 
for 1 hour, then incubated with the ﬁ  rst antibodies 
in TBST containing 5% non-fat dry milk. The 
membranes were then incubated with the sheep 
anti-mouse or rabbit Ig (Amersham) in TBST 
containing 2% non-fat dry milk. Bound antibody 
was detected with an enhanced chemiluminescence 
system (Amersham). The density of bands was 
quantiﬁ  ed by densitometric analysis using a Quan-
tity One Scan System (ATTO, Tokyo, Japan).
Antibodies used for Western blotting were the 
rabbit polyclonal, BRCA1 antibody,
 D-20 (Santa 
Cruz Biotechnology), ERK, pERK (Cell Signaling 
Technology, Inc. Danvers, MA), p53, p21, Bax, 
BCL-2 (Santa Cruz, St Louis, MO), and b-actin 
(Biomakor, Rehovot, Israel). For PARP assays, 
we used the monoclonal antibody #556494 (BD 
Bioscience. San Jose, CA U.S.A), which
 speciﬁ  -
cally recognizes the full-length Mr 116,000 PARP 
protein
 and its Mr 85,000 and 25,000 cleaved 
products.
Apoptosis assay
Quantitation of apoptotic cells was performed after 
72 hours of continuous drug exposure, using ApoS-
trand ELISA Apoptosis Detection Kit (BIOMOL 
International, LP) according to the manufacturer’s 
instructions. The ApoStrand ELISA is based on 
formamide denaturation and the detection of the 
denatured DNA with an antibody to single-stranded 




 48 hours after siRNA transfection, 
cells were either left untreated or
 exposed to 3 and 
6 Gy of ionizing radiation (Irradiation Equipment 
MBR-1505R2, Hitachi Medical corp., Tokyo, 
Japan).
Statistical analysis
The data are presented as the mean±SD. The 
signiﬁ  cance of differences was assessed by the 
Kruskal-Wallis test or by Mann-Whitney’s U test. 
Differences were considered to be signiﬁ  cant when 
P<0.05. These analyses were made using the Stat-
View system (Abacus, Berkeley, CA, U.S.A).
Results
BRCA1 is expressed in all of ovarian 
cancer cell lines
All of the 3 ovarian cancer cell lines, SKOV3, 
A2780 and A2780/CDDP, expressed endogenous 
BRCA1. Inhibition
 of endogenous BRCA1 expres-
sion after transfection with the BRCA1-siRNA 
oligonucleotide was conﬁ  rmed by RT-PCR and 
Western
 blot analyses. BRCA1 expression of these 
BRCA1-siRNA-transfected cells was decreased, 
compared with that in the same cell lines trans-
fected with the control oligonucleotide (Fig. 1).
Suppression of BRCA1 enhances 
the sensitivity to cisplatin in p53-wild 
ovarian cancer cells
We examined the role of BRCA1 expression in the 
sensitivity to chemotherapeutic
 agents in the pres-
ence or absence of endogenous BRCA1
 expression. 
After 3 days of drug exposure at a concentration of 
50, 100, 250, or 500  ×  10
–2 ng/ng of cisplatin, the 
number of cells was decreased under cisplatin treat-
ment in a dose-dependent manner in the control-
siRNA-transfected A2780 cells: to 81% of control 
with 250  ×  10
–2 ng/ng and to 69% of control with 
500  ×  10
–2 ng/ng cisplatin (Fig. 2a). BRCA1-siRNA 
transfection resulted in a signiﬁ  cant decrease in the 
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viable cell number of A2780 cells under cisplatin 
treatment: to 65% of control with 100   ×  10
–2 ng/ng, 
to 56% of control with 250    ×    10
–2 ng/ng, and to 
26% of control with 500    ×    10
–2 ng/ng cisplatin. 
Accordingly, BRCA1- siRNA-transfected A2780 
cells displayed a >5.3-fold
 increase in sensitive-
ness to cisplatin compared with the control cells. 
In contrast, SKOV3 and A2780/CDDP cells did not 
show the change in the sensitivity to cisplatin by 
BRCA1-siRNA transfection (Fig. 2a).
Suppression of BRCA1 does not 
change the sensitivity to paclitaxel, 
but enhances the irradiation effect in 
ovarian cancer cells
Sensitivity to paclitaxel was also examined in all 
of the 3 cell lines after inhibition
 of endogenous 
BRCA1 using BRCA1-siRNA. Although A2780 
cells showed a slight increase in the resistance to 
paclitaxel by transfection of BRCA1-siRNA, all of 
the 3 cell lines did not show signiﬁ  cant changes in 
the sensitivity to paclitaxel (Fig. 2b). 
Next, we examined the sensitivity to ionizing 
radiation. Exposure to 3 and 6Gy irradiation resulted 
in a signiﬁ  cant decrease in the number of viable 
A2780 cells after BRCA1-siRNA transfection 
compared to that of control cells (Fig. 2c). However, 
this effect was not observed in other cells. 
Suppression of BRCA1 does not affect 
the cell cycle of ovarian cancer cells 
To investigate whether the increase in chemo-
sensitivity by suppression of BRCA1 expression 
depends on the cell proliferation, we examined the 
effect of BRCA1-siRNA transfection on the cell 
growth of ovarian cancer cell lines. Growth curves 
using WST-1 assay did not show the signiﬁ  cant 
difference between BRCA1-siRNA-transfected
 
cells and the control cells in all of the 3 cell lines 
(Fig. 3). The cell-cycle analysis by FACScan 
showed that there was no signiﬁ  cant difference 
in the fractions, such as G1, S, and G2/M phases, 
between BRCA1-siRNA-transfected
 cells and the 
control cells in all of the 3 cell lines (Table 1).
Suppression of BRCA1 results in 
an increase of apoptosis under 
cisplatin treatment
Then, we examined whether the increased chemo-
sensitivity by BRCA1-siRNA transfection was due 
to activation of apoptosis. Suppression of BRCA1 
in A2780 cells resulted in a dramatic increase in 
the apoptotic cells under treatment with cisplatin 
in a dose-dependent manner (Fig. 4a). In contrast, 
BRCA1-siRNA transfection into A2780/CDDP 
and SKOV3 cells did not show a statistically 
signiﬁ  cant difference in the apoptosis (Fig. 4a). 
Figure 1. Ovarian cancer cells express BRCA1 mRNA and protein, which is suppressed by BRCA1-speciﬁ  c siRNA transfection.
RT-PCR (a) and Western blot (b) analyses show that all of the 3 ovarian cancer cell lines, SKOV3, A2780 and A2780/CDDP, express en-
dendogenous BRCA1 mRNA and protein. Transfection of the BRCA1-speciﬁ  c siRNA suppresses the expression of BRCA1 in all of the 3 
cell lines. Lanes 1, SKOV3; 2, A2780; 3, A2780/CDDP.
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Figure 2. Suppression of BRCA1 expression results in the increase in the cisplatin sensitivity in A2780 ovarian cancer cells.
WST-1 assay shows that effect of cisplatin (a), paxlitaxol (b), and irradiation (c) on the viable cell number. Transfection of
BRCA1-siRNA results in the increase in the sensitivity to cisplatin in p53-wild A2780 cells, but not in p53-mutated A2780/CDDP or in
p53-deleted SKOV3 cells. Sensitivity to paclitaxel is not changed in all of the 3 cell lines. Values indicate means ±SE. Signiﬁ  cance of
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Exposure to 3 and 6 Gy irradiation also resulted 
in a signiﬁ  cant increase in the apoptotic cells in 
BRCA1-siRNA-transfected A2780 cells (Fig. 4b). 
The band density of the PARP Mr 85,000 product 
cleaved from the Mr 116,000 PARP, which is an 
early hallmark of apoptosis, was 1.9 fold increased 
in BRCA1-siRNA-transfected A2780 cells under 
cisplatin treatment (Fig. 4c).
Increase of apoptosis is associated 
with up-regulation of p53 and p21
Finally, we analyzed the expression of the 
apoptosis-related gene products, p53, p21, Bax, 
and Bcl-2. Neither Bax nor Bcl-2 expression 
was not different between BRCA1-siRNA-trans-
fected A2780 cells and control cells (Fig. 5a). In 
contrast, the increased expression of p53 and p21 
under cisplatin treatment was stronger in BRCA1-
Figure 3. Suppression of BRCA1 expression does not affect the cell proliferation of ovarian cancer cells.
There is no signiﬁ  cant differences in the growth curves between BRCA1-siRNA- transfected cells and control-oligonucleotide-transfected 
cells. Values indicate means ±SE.
siRNA-transfected A2780 cells than control cells 
(Fig. 5b). After the irradiation, up-regulation of 
p53 and p21 was stronger in BRCA1-siRNA-
transfected A2780 cells than in control cells
(Fig. 5c): for p53 increase in 3.3 and 1.8 fold at 3 
and 6 Gy, respectively, and for p21 increase in 2.0 
and 1.5 fold at 3 and 6 Gy, respectively.
Discussion
Our previous study on 76 patients with ovarian 
carcinoma treated during the period of cisplatin-
based chemotherapy before the introduction of 
paclitaxel revealed that there was a tendency 
towards a poorer prognosis in advanced stage 
patients with positive BRCA1 expression, i.e., 
overall survival was 17.7 ± 8.9 months for BRCA1-
positive versus 31.6  ±  25.9 months for BRCA1-
negative patients (Wang et al. 2004). There have 
Table 1. BRCA1 suppression does not affect the cell cycle of ovarian cancer cells.
 A2780  A2780/CDDP  SKOV3
  control  BRCA1 si  control  BRCA1 si  control  BRCA1 si 
G1    52.57±5.11% 50.03±4.88% 48.87±4.76% 44.77±5.71% 45.07±4.1%  43.03±2.71%
S    16.43±3.18% 19.33±2.81% 10.89±2.18% 10.40±3.23%    9.43±5.18%  9.39±1.86%
G2/M   19.73±2.50% 21.37±2.76% 28.83±2.44% 29.39±3.50% 23.03±1.50% 23.99±2.90% 
Values indicate means ±SE. 
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Figure 4. BRCA1 suppression increases the apoptosis of ovarian cancer cells under cisplatin treatment or under irradiation 
Apostrand assay shows that cisplatin-induced apoptosis were signiﬁ  cantly increased in BRCA1-siRNA-transfected A2780 cells (a). After expo-
sure to 3 and 6 Gy irradiation, the increase in apoptosis was observed in BRCA1-siRNA-transfected A2780 cells, but not in other cells (b).
PARP cleavage assay (c) demonstrating the presence of the cleaved PARP Mr 85,000 fragment indicative of apoptosis in A2780 cells 
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Figure 5. BRCA1 suppression increases the expression of p53 and p21 under cisplatin treatment in ovarian cancer cells.
Among the apoptosis-related molecules, expression of both Bax and Bcl2 is not changed between BRCA1-siRNA-transfected cells and 
control cells under cisplatin treatment (a). However, expression of p53 and p21 is increased under cisplatin treatment in the BRCA1-siRNA-
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also been reports on the better survival in patients 
with BRCA1-negative tumor compared with those 
with BRCA1-positive one, as exempliﬁ  ed in breast 
and lung carcinomas (Rubin 1996; Ben David 
et al. 2002; Taron et al. 2004). These in vivo data 
prompted us to analyze the role of BRCA1 in sensi-
tivity to chemotherapeutic agents. In this study, we 
examined the chemosensitivity under suppression 
of endogenous BRCA1 expression using BRCA1-
speciﬁ  c siRNA in ovarian cancer cell lines. Our 
results showed that the sensitivity to cisplatin 
was signiﬁ  cantly increased by BRCA1 suppres-
sion in A2780 ovarian cancer cells. The effect of 
BRCA1 suppression on the chemosensitivity has 
previously been studied mainly in breast cancer 
cell lines. Breast cancer cells carrying wild-type 
BRCA1, such as MCF-7 and MDA-MB231, were 
more resistant to cisplatin than BRCA1-mutant 
HCC1937 cells (Tassone et al. 2003). In BRCA1-
mutant breast cancer cells, reconstitution of 
BRCA1 resulted in the cisplatin resistance (Quinn 
JE et al. 2003). Husain et al. (1998) demonstrated 
that acquisition of further resistance to cisplatin 
was associated with an increase in the expression 
of BRCA1 in MCF-7 cells. In a previous report 
on human ovarian cancer cells, up-regulation of 
BRCA1 was associated with more resistance to 
cisplatin, and the suppression of BRCA1 using its 
antisense oligonucleotide restored cisplatin sensi-
tivity (Husain et al. 1998). All of these ﬁ  ndings 
indicate that BRCA1 status is very important in the 
sensitivity to cisplatin in various cancer cells.
More interesting issue is the role of BRCA1 on 
the sensitivity to paclitaxel. In our study, suppres-
sion of BRCA1 did not show the significant 
changes in the sensitivity in all of the 3 ovarian 
cancer cell lines. Cisplatin is an intra-strand
DNA cross-linking
 agent that forms DNA adducts, 
and also causes double-stranded DNA breaks by 
introducing inter-strand
 links (Metzler 1986), 
whereas paclitaxel is an anti-microtubule agent 
disrupting the mitotic spindle. Therefore, the 
discrepancy in the effect of BRCA1 suppression 
between cisplatin and paclitaxel is possibly due 
to their differences in the signal pathways for the 
chemotherapeutic effect (Kennedy et al. 2004). 
This is also supported by the fact that BRCA1 
suppression also resulted in an increase in the 
sensitivity to ionizing radiation, which also induces 
DNA damages including double-strand breaks. 
Previous in vitro experiments using breast cancer 
cells showed that BRCA1-negative cells were less 
sensitive to paxlitaxel than BRCA1-positive cells 
(Tassone et al. 2003), and that BRCA1 might be 
required for the induction of apoptosis in response 
to paclitaxel in breast cancer cells (Quinn et al. 
2003). However, a clinical study showed that 
locally advanced breast carcinomas negative for 
BRCA1 expression responded well to taxens, 
compared with those positive for BRCA1 (Egawa 
et al. 2003). In mouse ovarian cancer cells, Sylvain 
et al. (2002) demonstrated that suppression of 
BRCA1 using the truncated mutant increased the 
paclitaxel sensitivity. Zhou et al. (2003) reported 
that BRCA1 mutation in human ovarian cancer 
cell line increased the sensitivity to paclitaxel. 
Although we did not ﬁ  nd the signiﬁ  cant changes 
in the paclitaxel sensitivity under suppression of 
BRCA1, further studies are needed to clarify the 
actual role of BRCA1 in the response to taxens in 
ovarian carcinoma cells.
BRCA1 has also been reported to contribute 
to the maintenance of genome integrity. BRCA1 
deﬁ  ciency increases the mutation rate of gene 
such as p53 (Deng and Wang 2003). BRCA1 was 
also shown to bind directly to p53 (Derbyshire 
et al. 2002; Chai et al. 1999), and to enhance 
trans-activating activity and stability of p53 
(Somasundaram et al. 1999; Fabbro et al. 2004). 
These ﬁ  ndings prompted us to analyze the effect 
of BRCA1 suppression on the chemosensitivity 
and its relevance to the p53 status. In this study, 
the increased sensitivity to cisplatin by BRCA1 
suppression was observed in p53-wild A2780 
cells, but not in p53-mutated A2780/CDDP cells 
nor in p53-deleted SKOV3 cells. This seem to be 
consistent with that BRCA1-knockout mice die 
in early gestation, whereas additional loss of p53 
function is able to rescue the same mice (Hakem 
et al. 1997). Therefore, normal p53 function may 
be an essential component for induction of cell 
death due to DNA damage by cisplatin treatment 
and irradiation. Our ﬁ  ndings suggest that BRCA1 
cooperates with p53 in the response to DNA 
damage in ovarian cancer cells. However, BRCA1-
negative ovarian carcinomas frequently show p53 
overexpression suggesting p53-mutation (Wang
et al. 2003). Further studies are needed to verify the 
role of p53 in BRCA1-dependent chemosensitivity 
in ovarian cancer cells.
Chemotherapeutic effect is usually inﬂ  uenced 
by the cell proliferation and the cell cycle, and 
apoptosis is the ﬁ  nal common pathway of cell 
death due to chemotherapy and irradiation. Our 
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study showed that BRCA1 suppression affected 
neither the cell proliferation nor the cell cycle of 
ovarian cancer cells. However, increased induc-
tion of apoptosis was linked to the increased 
sensitivity to cisplatin and to irradiation under 
BRCA1 suppression in the A2780 cells. Then, we 
analyzed which pathway is involved in the apop-
tosis in BRCA1 suppression. Among the apoptosis-
related molecules, BRCA1 suppression along with 
cisplatin treatment did not change the expression 
levels of Bax and Bcl-2, but up-regulated both 
p53 and p21 expression in p53-wild A2780 cells. 
It has also been reported that BRCA1-knockout 
embryos die in early development being associ-
ated with elevated expression of p21 (Hakem et al. 
1996, 1998). These ﬁ  ndings suggest that p53–p21 
pathway plays an important role in the apoptotic 
cell death due to BRCA1 suppression. Although it 
has been known that p53 is involved in the induc-
tion of p21(WAF1/Cip1)(Zuo et al. 1998), this is 
the ﬁ  rst report on the relevance of p53 and p21 
to the chemosensitivity in BRCA1-suppressed 
ovarian cancer cells. Interestingly, we recently 
found that activated form of MAP kinase (ERK) 
was decreased in BRCA1-suppressed ovarian 
carcinoma cells (data not shown), and this may 
be consistent with that activated ERK is reported 
to work as anti-apoptotic signal (Ohmichi et al. 
2005).
In summary, the suppression of BRCA1 expres-
sion enhances the cisplatin sensitivity and induces 
apoptosis possibly via the p53–p21 pathway. 
In contrast, it does not affect the sensitivity to 
paxlitaxel. Accordingly, the expression of BRCA1 
might be an important biomarker for the sensitivity 
to chemotherapeutic agents. Prospective studies are 
needed to verify its predictive value in the chemo-
therapy for ovarian carcinoma patients.
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